Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Differential proteomics of peripheral blood CD14+ monocytes in the luminal breast carcinoma subtypes: A primary study

ABSTRACT: We performed differential proteomic analysis of CD14+ monocytes from peripheral blood of BC-confirmed patients, benign individuals vs. HCs. Results revealed DEPs found across all studied cohorts such as SRSF1, CSTB, KRT2, KRT5, HEL-S-11, APOB, APOE, and ITGA2B. Herein, APOB, HEL-S-11, KRT5, and SRS1 had AUC ≥ 0.6, and are assumed as feasible classifiers of random individuals. Comparison of benign vs. HCs revealed KRT2 and KRT5, found as DAPs common for all tested groups. ENO1 found in LumA, KRT1 in LumB-HER2-, and AIDB in LumB-HER2+, were interesting BC-related DEPs analysed among top 10 hits. The GSEA analysis of LumA vs. HCs revealed enrichment of Ca2+ GNRH and LTM signalling pathways. The Ribosome and Lysosome signalling pathways were further found enriched in LumB-HER2- vs. HCs comparison and the MYC Targets V2 pathway found enriched in LumB-HER2+.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Monocyte, Cd14-positive Monocyte, Blood

DISEASE(S): Breast Cancer

SUBMITTER: Miroslav Marcin

LAB HEAD: Ján Sabo

PROVIDER: PXD068744 | Pride | 2026-03-09

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20230405_metoda17_Z14D_meranie1.raw	Raw
	20230412_metoda17_Z10D_meranie1.raw	Raw
	20230412_metoda17_Z15D_meranie1.raw	Raw
	20230412_metoda17_Z2D_meranie1.raw	Raw
	20230412_metoda17_Z5D_meranie1.raw	Raw

Items per page:

1 - 5 of 180

Publications

Peripheral blood CD14 + monocytes in luminal breast carcinoma subtypes: in preliminary research and overview of candidate biomarker proteins.

Alexovič Michal M Bober Peter P Marcin Miroslav M Parnica Jozef J Marcin Michal M Lenárt Marek M Tóth Dávid D Radoňak Jozef J Urdzík Peter P Sabo Ján J

Scientific reports 20260210

PMID: 41663524

Similar Datasets

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells

Project description:Objective: Trastuzumab has been used for the treatment of HER2-positive breast cancer (BC). However, a subset of BC patients exhibited resistance to trastuzumab therapy. Thus, clarifying the molecular mechanism of trastuzumab treatment will be beneficial to improve the treatment of HER2-positive BC patients. In this study, we identified trastuzumab-responsive microRNAs that are involved in the therapeutic effects of trastuzumab. Methods and results: RNA samples were obtained from HER2-positive (SKBR3 and BT474) and HER2-negetive (MCF7 and MDA-MB-231) cells with and without trastuzumab treatment for 6 days. Next, we conducted a microRNA profiling analysis using these samples to screen those microRNAs that were up- or downregulated only in HER2-positive cells. This analysis identified miR-26a and miR-30b as trastuzumab-inducible microRNAs. Transfecting miR-26a and miR-30b induced cell growth suppression in the BC cells by 40% and 32%, respectively. A cell cycle analysis showed that these microRNAs induced G1 arrest in HER2-positive BC cells as trastuzumab did. An Annexin-V assay revealed that miR-26a but not miR-30b induced apoptosis in HER2-positive BC cells. Using the prediction algorithms for microRNA targets, we identified cyclin E2 (CCNE2) as a target gene of miR-30b. A luciferase-based reporter assay demonstrated that miR-30b post-transcriptionally reduced 27% (p=0.005) of the gene expression by interacting with two binding sites in the 3’-UTR of CCNE2. Conclusion: In BC cells, trastuzumab modulated the expression of a subset of microRNAs, including miR-26a and miR-30b. The upregulation of miR-30b by trastuzumab may play a biological role in trastuzumab-induced cell growth inhibition by targeting CCNE2. We obtained microRNA expression profiles of breast cancer cell lines, MCF7, MDA-MB-231, SKBR3, and BT474, with or without trastuzumab (4microgram/mL) treatment.

2012-06-02 | E-GEOD-38415 | biostudies-arrayexpress

An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer

Project description:Resistance to CDK4/6 inhibitors leads to treatment failure and disease progression in women with HR+HER2- breast cancer (BC). We delineated a hypoxia-sensitive, CCL2-dependent pathway recruiting IL17A-secreting γδ T cells to mouse HR+HER2- BCs upon CDK4/6 inhibition, resulting in repolarization of tumor-associated macrophages (TAMs) towards an immunosuppressive CX3CR1+ phenotype associated with resistance. Increased IL17A signaling and intratumoral γδ T cell abundance positively correlated with advanced grade and/or reduced survival in two cohorts of HR+HER2- BC patients. Circulating γδ T cells and plasma CCL2 levels negatively correlated with progression in an independent series of patients with HR+HER2- BC receiving CDK4/6 inhibitors. Intratumoral γδ T cells were increased in post- vs pre-treatment biopsies from HR+HER2- BC patients relapsing on CDK4/6 inhibitors. CX3CR1+ TAMs had negative prognostic impact in women with HR+HER2- BC receiving neoadjuvant PD-1 blockage and radiotherapy. Thus, γδ T cells and CX3XR1+ TAMs may favor resistance to CDK4/6 inhibitors in HR+HER2- BC patients.

2025-05-09 | GSE296805 | GEO

An immunological mechanism of resistance to CDK4/6 inhibitors in breast cancer

2025-05-09 | GSE296798 | GEO

Transcription profiling of mouse tracheal basal cells

Project description:Epithelial basal cells (BCs) are an important stem cell population of the airways. We purified BCs from a KRT5-GFP transgenic mouse line and used Affymetrix arrays to compare there gene expression to that of non-BC epithelium. Experiment Overall Design: Three populations of cells were obtained by FACS: 1. KRT5-GFP-, lectin- columnar epithelium. 2. KRT5-GFP-, lectin+ BCs. 3. KRT5-GFP+, lectin+ BCs. Three biological replicates of each sample were hybridized to Affymetrix microarray.

2009-07-11 | E-GEOD-15724 | biostudies-arrayexpress

SNP arrays of BT474 Latpatinib and/or Trastuzumab resistant cell lines for copy number analysis.

Project description:Targeting HER2 with lapatinib (L), trastuzumab (T), or the LT combination, is effective in HER2+ breast cancer (BC), but de novo and acquired resistance commonly occur. The purpose of this experiment was to investigate the somatic alterations found in Lapatinib and/or Trastuzumab resistant cells lines.

2019-06-21 | GSE83608 | GEO

MicroRNA profiling of monocytes in LTNPs and Chronic HIV patients (CHI)

Project description:We extracted total RNA from monocytes in 3 different patient groups, LTNPs, CHIs and Healthy Controls (HCs) in order to determine differentially expressed miRNA between these groups and to compare the results to a previous study on the same patients CD4+ T cells (GSE24022). In this study total RNA was extracted from 8 LTNPs, 8 CHIs and 8 HCs before being run on an agilent miRNA microarray

2014-01-16 | E-GEOD-38556 | biostudies-arrayexpress

Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells

2012-06-03 | GSE38415 | GEO

Lung extracellular matrix modulates KRT5+ basal cell activity in pulmonary fibrosis

Project description:Aberrant expansion of KRT5+ basal cells in the distal lung accompanies progressive alveolar epithelial cell loss and tissue remodelling during fibrogenesis in idiopathic pulmonary fibrosis (IPF). The mechanisms determining activity of KRT5+ cells in IPF have not been delineated. Here, we show an association between KRT5+ cells in human fibrotic lung and regional differences in collagen topography. In vitro, KRT5+ cell migratory characteristics and expression of remodelling genes are modulated by extracellular matrix (ECM) composition and organisation. Mass spectrometry-based proteomics revealed compositional differences in the matrisome secreted by primary human lung fibroblasts (HLF) from IPF patients compared to controls. Over-expression of ECM glycoprotein, Secreted Protein Acidic and Cysteine Rich (SPARC) in the IPF HLF matrisome restricts KRT5+ cell migration in vitro. Together, our findings demonstrate that changes to the ECM in IPF directly influence KRT5+ cell behaviour and function contributing to remodelling events in the fibrotic niche.

2023-09-28 | PXD037236 | Pride

Gene expression in mouse tracheal basal cells

2009-07-02 | GSE15724 | GEO

Blood-brain barrier dysfunction in brain metastasis formation in HER2-positive breast cancer

Project description:we investigated the role of bioactive molecules secreted by HER2+ BC cells in BBB dysfunction during the formation of the pre-metastatic niche before the onset of BrM. We demonstrate that systemic signaling derived from brain metastatic HER2+ primary tumors instigates BBB dysfunction

2025-05-06 | PXD051579 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data